Table 3.
Clinical features of patients with prefibrotic/early myelofibrosis who progressed to overt myelofibrosis (N=10).
| At pre-PMF diagnosis | At overt PMF diagnosis | P a) | |
|---|---|---|---|
| Age (yr), median (range) | 62 (16–72) | 69.5 (34–79) | |
| Palpable splenomegaly, N (%) | 2 (20.0) | 7 (70.0) | 0.025 |
| Laboratory findings | |||
| WBC, ×109/L | 12.6±5.3 | 12.6±10.9 | 0.987 |
| Monocyte, ×109/L | 0.8±0.3 | 0.5±0.4 | 0.119 |
| Hemoglobin, g/dL | 13.2±2.4 | 9.2±2.5 | 0.004 |
| Platelet, ×109/L | 1,186.3±567.7 | 450.7±196.5 | 0.003 |
| LDH, ×UNL | 1.5±0.4 | 2.8±0.5 | 0.005 |
| Leukoerythrolastosis, N (%) | 2 (20.0) | 9 (90.0) | 0.002 |
| Abnormal karyotype, N (%) | 1 (10.0) | 7 (70.0) | 0.006 |
| IPSS, N (%) | 0.004 | ||
| Low | 7 (70.0) | 1 (10.0) | |
| Intermediate-1 | 3 (30.0) | 1 (10.0) | |
| Intermediate-2 | 0 (0.0) | 3 (30.0) | |
| High | 0 (0.0) | 5 (50.0) |
a)Data presented as mean±SD were analyzed using Student’s t-test for paired samples; data presented as percentages were analyzed using the chi-square test.
Abbreviations: LDH, lactate dehydrogenase; IPSS, International Prognostic Scoring System; pre-PMF, prefibrotic/early primary myelofibrosis; UNL, upper normal limit.